Item 8.01. Other Events.

On February 2, 2023, NRx Pharmaceuticals, Inc. (the "Company ") convened a special meeting of stockholders (the "Special Meeting"). As of the close of business on January 9, 2023, the record date of the Special Meeting, there were 67,690,914 shares of common stock, par value $0.001 per share of the Company (the "Common Stock") outstanding, each of which was entitled to one vote on each proposal at the Special Meeting.

At that time, there were not present or represented by proxy a sufficient number of shares of Common Stock to constitute a quorum. Accordingly, the Company adjourned the Special Meeting without any business being conducted, in order to allow time to achieve quorum and to allow the Company's stockholders additional time to vote on the proposal set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on January 10, 2023 (the "Proxy Statement").

The adjourned Special Meeting will reconvene on February 17, 2023 at 11:00 a.m. local time, to be held in virtual format at: https://www.cstproxy.com/nrxpharma/2023.

The close of business on January 9, 2023 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting. Stockholders of the Company who have previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action.

No changes have been made to the proposal to be voted on by stockholders at the Special Meeting. The Company encourages all of its stockholders to read the Proxy Statement, which is available free of charge on the SEC's website at www.sec.gov.

During the period of adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposal set forth in the Proxy Statement. The Company encourages all stockholders who have not yet voted to do so promptly.

© Edgar Online, source Glimpses